Skip to search formSkip to main contentSkip to account menu

ICRF-159

Known as: ICI 59118, ICRF 159, ICRF159 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Profound modification of the structure and arrangement of the blood vessels has been shown in tumours after treatment with ICRF… 
Review
1998
Review
1998
Highly Cited
1998
Highly Cited
1998
Anticancer drugs targeted to the nuclear enzyme DNA topoisomerase II are classified as poisons that lead to DNA breaks or… 
Highly Cited
1995
Highly Cited
1995
Bisdioxopiperazines such as ICRF-159 and ICRF-193 have been shown to inhibit DNA topoisomerase II. To determine the molecular… 
Highly Cited
1994
Highly Cited
1994
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… 
Highly Cited
1991
Highly Cited
1991
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… 
Highly Cited
1980
Highly Cited
1980
This paper describes our experience with the use of razoxane (ICRF 159), a new anti‐mitotic drug, in the treatment of thirty‐six… 
1974
1974
ICRF 159, an antimitotic agent that increases the antitumor activity of most antineoplastic drugs, has now also been shown to… 
Highly Cited
1969
Highly Cited
1969
THE aim of cancer chemotherapy to destroy the last malignant cell may be unnecessarily ambitious if inhibition of metastases…